A new nanoparticle vaccine developed by MIT researchers could assist efforts to eradicate polio worldwide. The vaccine, which delivers multiple doses in just one injection, could make it easier to immunize children in remote regions of Pakistan and other countries where the disease is still found.
While the number of reported cases of polio dropped by 99 percent worldwide between 1988 and 2013, according to the Centers for Disease Control, the disease has not been completely eradicated, in part because of the difficulty in reaching children in remote areas to give them the two to four polio vaccine injections required to build up immunity.
“Having a one-shot vaccine that can elicit full protection could be very valuable in being able to achieve eradication,” says Ana Jaklenec, a research scientist at MIT’s Koch Institute for Integrative Cancer Research and one of the senior authors of the paper.
Robert Langer, the David H. Koch Institute Professor at MIT, is also a senior author of the study, which appears in the Proceedings of the National Academy of Sciences the week of May 21. Stephany Tzeng, a former MIT postdoc who is now a research associate at Johns Hopkins University School of Medicine, is the paper’s lead author.
“We are very excited about the approaches and results in this paper, which I hope will someday lead to better vaccines for patients around the world,” Langer says.
There are no drugs against poliovirus, and in about 1 percent of cases, it enters the nervous system, where it can cause paralysis. The first polio vaccine, also called the Salk vaccine, was developed in the 1950s. This vaccine consists of an inactivated version of the virus, which is usually given as a series of two to four injections, beginning at 2 months of age. In 1961, an oral vaccine was developed, which offers some protection with only one dose but is more effective with two to three doses.
The oral vaccine, which consists of a virus that has reduced virulence but is still viable, has been phased out in most countries because in very rare cases, it can mutate to a virulent form and cause infection. It is still used in some developing countries, however, because it is easier to administer the drops than to reach children for multiple injections of the Salk vaccine.
For polio eradication efforts to succeed, the oral vaccine must be completely phased out, to eliminate the chance of the virus reactivating in an immunized person. Several years ago, Langer’s lab received funding from the Bill and Melinda Gates Foundation to try to develop an injectable vaccine that could be given just once but carry multiple doses.
“The goal is to ensure that everyone globally is immunized,” Jaklenec says. “Children in some of these hard-to-reach developing world locations tend to not get the full series of shots necessary for protection.”
To create a single-injection vaccine, the MIT team encapsulated the inactivated polio vaccine in a biodegradable polymer known as PLGA. This polymer can be designed to degrade after a certain period of time, allowing the researchers to control when the vaccine is released.
“There’s always a little bit of vaccine that’s left on the surface or very close to the surface of the particle, and as soon as we put it in the body, whatever is at the surface can just diffuse away. That’s the initial burst,” Tzeng says. “Then the particles sit at the injection site and over time, as the polymer degrades, they release the vaccine in bursts at defined time points, based on the degradation rate of the polymer.”
The researchers had to overcome one major obstacle that has stymied previous efforts to use PLGA for polio vaccine delivery: The polymer breaks down into byproducts called glycolic acid and lactic acid, and these acids can harm the virus so that it no longer provokes the right kind of antibody response.
To prevent this from happening, the MIT team added positively charged polymers to their particles. These polymers act as “proton sponges,” sopping up extra protons and making the environment less acidic, allowing the virus to remain stable in the body.
“I think the beauty of the paper is that the traditional microparticle formulation design principles for antigen stabilization are applicable to the delivery of a very complex antigen system. Single dose vaccination for developing world applications is a Holy Grail, and they are getting close,” says David Putnam, a professor of biomedical engineering and chemical and biomolecular engineering at Cornell University who was not involved in the research.
In the PNAS study, the researchers designed particles that would deliver an initial burst at the time of injection, followed by a second release about 25 days later. They injected the particles into rats, then sent blood samples from the immunized rats to the Centers for Disease Control for testing. Those studies revealed that the blood samples from rats immunized with the single-injection particle vaccine had an antibody response against poliovirus just as strong as, or stronger than, antibodies from rats that received two injections of Salk polio vaccine.
To deliver more than two doses, the researchers say they could design particles that release vaccine at injection and one month later, and mix them with particles that release at injection and two months later, resulting in three overall doses, each a month apart. The polymers that the researchers used in the vaccines are already FDA-approved for use in humans, so they hope to soon be able to test the vaccines in clinical trials.
Learn more: A single-injection vaccine for the polio virus
The Latest on: Nanoparticle vaccine
via Google News
The Latest on: Nanoparticle vaccine
- OSU researcher to help create gonorrhea vaccine on April 17, 2019 at 9:14 pm
She’ll also be in charge of a project that will study incorporating antigens into nanoparticle platforms called nanodiscs, an attempt to increase vaccine potency and efficacy. In addition to OSU and ... […]
- First-In-Human Trial Begins On Universal Flu Vaccine, Older Adults Still Encouraged To Vaccinate on April 16, 2019 at 7:20 am
A team of VRC scientists developed the vaccine prototype. “It displays part of hemagglutinin (HA), an influenza protein, on the surface of a microscopic nanoparticle made of nonhuman ferritin,” the ... […]
- Novavax Scientific Leadership to Present RSV Maternal Immunization Program Phase 3 Data and Participate in Panel on COPD at World Vaccine Congress on April 9, 2019 at 7:14 pm
Details are as follows: About ResVax™ ResVax is an RSV fusion (F) protein recombinant nanoparticle vaccine with aluminum phosphate as an adjuvant. Novavax is developing ResVax to protect infants ... […]
- First Human Trial of Universal Flu Vaccine Underway on April 7, 2019 at 7:29 am
"A team of VRC scientists developed the universal influenza vaccine prototype. It displays part of hemagglutinin (HA), an influenza protein, on the surface of a microscopic nanoparticle made of ... […]
- First-In-Human Trial of a Universal Influenza Vaccine Candidate Begins, NIH Reports on April 5, 2019 at 6:54 pm
Initial data from an earlier VRC clinical trial evaluating a ferritin nanoparticle vaccine that included both hemagglutinin head and stem showed that the platform is safe and well-tolerated in humans. […]
- NIH begins first-in-human trial of universal influenza vaccine candidate on April 5, 2019 at 2:30 am
It displays part of hemagglutinin (HA), an influenza protein, on the surface of a microscopic nanoparticle made of nonhuman ferritin. Ferritin is a natural protein that can be found in cells from all ... […]
- NIH Begins Trial of Potential Universal Flu Vaccine on April 4, 2019 at 9:24 am
H1ssF_3928 displays part of hemagglutinin (HA), an influenza protein, on the surface of a microscopic nanoparticle made of nonhuman ferritin, NIH said in a statement. Ferritin is a natural protein ... […]
- NIH unveils a vaccine candidate for universal flu jab as first-in-human studies get underway on April 4, 2019 at 4:32 am
The new vaccine ditches the head entirely in favor of the stem, which is more constant among different influenza strains. The HA stem is tagged onto a microscopic nanoparticle made of nonhuman ... […]
- Computer-designed Nanoparticle Vaccine Candidate for Respiratory Syncytial Virus on March 11, 2019 at 4:35 pm
Scientists have designed a first-of-its-kind nanoparticle vaccine candidate for respiratory syncytial virus. RSV is second only to malaria as a cause of infant mortality worldwide. The new vaccine ... […]
via Bing News